keyword
MENU ▼
Read by QxMD icon Read
search

Metabolic syndrome antipsychotic

keyword
https://www.readbyqxmd.com/read/29449054/second-generation-antipsychotic-induced-mitochondrial-alterations-implications-for-increased-risk-of-metabolic-syndrome-in-patients-with-schizophrenia
#1
Giselli Scaini, João Quevedo, Dawn Velligan, David L Roberts, Henriette Raventos, Consuelo Walss-Bass
Metabolic syndrome (MetS) is seen more frequently in persons with schizophrenia than in the general population, and these metabolic abnormalities are further aggravated by second generation antipsychotic (SGA) drugs. Although the underlying mechanisms responsible for the increased prevalence of MetS among patients under SGA treatment are not well understood, alterations in mitochondria function have been implicated. We performed a comprehensive evaluation of the role of mitochondrial dysfunction in the pathophysiology of drug-induced MetS in schizophrenia...
February 12, 2018: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29441581/genetic-polymorphisms-of-htr2c-lep-and-lepr-on-metabolic-syndromes-in-patients-treated-with-atypical-antipsychotic-drugs
#2
Apichaya Puangpetch, Weerapon Unaharassamee, Napa Jiratjintana, Napatrupron Koomdee, Chonlaphat Sukasem
OBJECTIVE: Single nucleotide polymorphisms in serotonin 2C receptor (HTR2C), leptin (LEP), and leptin receptor (LEPR) genes are reportedly associated with the presence of metabolic syndrome (MS). We investigated whether HTR2C:rs518147 (-697G/C), rs12836771 (A/G), LEP: rs7799039 (-2548G/A) and LEPR:rs1137101 (668A/G) are related to MS in psychotic disorder patients treated with atypical antipsychotics. METHODS: A cross-sectional study including 200 patients was conducted; genetic polymorphisms in HTR2C (rs518147 and rs12836771), LEP (rs7799039) and LEPR (rs1137101) were genotyped...
February 13, 2018: Journal of Pharmacy and Pharmacology
https://www.readbyqxmd.com/read/29397899/sodium-benzoate-a-d-amino-acid-oxidase-inhibitor-added-to-clozapine-for-the-treatment-of-schizophrenia-a-randomized-double-blind-placebo-controlled-trial
#3
Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang, Hsien-Yuan Lane
BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine...
December 26, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/29320364/cardiometabolic-effects-of-psychotropic-medications
#4
REVIEW
Oluchi Abosi, Sneha Lopes, Samantha Schmitz, Jess G Fiedorowicz
Background Many psychiatric disorders including schizophrenia, bipolar disorder and major depression convey an excess burden of cardiovascular morbidity and mortality. The medications used to treat these conditions may further adversely affect cardiovascular risk and exacerbate health disparities for vulnerable populations. There is a clinical need to appreciate the cardiometabolic adverse effects of psychotropic medications. Methods This paper reviews the most relevant cardiometabolic effects of psychotropic medications, organized around the components of metabolic syndrome...
January 10, 2018: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/29285684/socioeconomic-disparities-and-metabolic-risk-in-veterans-with-serious-mental-illness
#5
Stanley N Caroff, Shirley H Leong, Daisy Ng-Mak, E Cabrina Campbell, Rosalind M Berkowitz, Krithika Rajagopalan, Chien-Chia Chuang, Antony Loebel
Socioeconomic disparities were assessed in predicting metabolic risk among veterans with serious mental illness. Veterans with schizophrenia, schizoaffective, or bipolar disorders were identified in VISN 4 facilities from 10/1/2010 to 9/30/2012. Differences between patients with and without metabolic syndrome were compared using t-tests, Chi square tests and multivariate logistic regressions. Among 10,132 veterans with mental illness, 48.8% had metabolic syndrome. Multivariate logistic regression analysis confirmed that patients with metabolic syndrome were significantly more likely to be older, male, African-American, married, and receiving disability pensions but less likely to be homeless...
December 28, 2017: Community Mental Health Journal
https://www.readbyqxmd.com/read/29220825/effects-of-nutritional-education-on-weight-change-and-metabolic-abnormalities-among-patients-with-schizophrenia-in-japan-a-randomized-controlled-trial
#6
Norio Sugawara, Toyoaki Sagae, Norio Yasui-Furukori, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Takuro Sugai, Hiroshi Matsuda, Yutaro Suzuki, Yuji Ozeki, Kurefu Okamoto, Toshiyuki Someya
OBJECTIVE: Patients with schizophrenia have a higher prevalence of metabolic syndrome (MetS) than the general population. Minimizing weight gain and metabolic abnormalities in a population with an already high prevalence of obesity is of clinical and social importance. This randomized controlled trial investigated the effect of monthly nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan. METHODS: From July 2014 to December 2014, we recruited 265 obese patients who had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder...
December 4, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29210867/antipsychotic-polypharmacy-and-its-relation-to-metabolic-syndrome-in-patients-with-schizophrenia-an-egyptian-study
#7
Dina M Aly El-Gabry, Karim Abdel Aziz, Tarek Okasha, Hanan Azzam, Ahmed Okasha
PURPOSE/BACKGROUND: Few studies have examined the relationship between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. Some studies suggest that antipsychotic polypharmacy may be associated with greater metabolic risk, whereas other studies suggest that this is uncertain. To date, there have been no studies in Egypt or the Arab world that have investigated this relationship. We sought to compare subjects with schizophrenia receiving antipsychotic polypharmacy and monotherapy as regards metabolic outcomes and to investigate medication-related factors associated with metabolic syndrome...
November 28, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29197134/assessment-of-cardiovascular-risk-in-an-italian-psychiatric-outpatient-sample-a-chart-review-of-patients-treated-with-second-generation-antipsychotics
#8
Elena Severi, Maria Ferrara, Enrico Tedeschini, Francesca Vacca, Francesco Mungai, Rocco Amendolara, Flavia Baccari, Fabrizio Starace
Despite the call by the scientific community for a systematic monitoring of physical health in people with psychiatric illnesses, national and international audits have reported poor quality of cardiovascular risk assessments and management in this vulnerable population. Available evidence indicates that in people affected by mental illness, life expectancy is reduced by 10-20 years, mainly due to cardiovascular accidents and metabolic syndrome (MetS)-related diseases. The primary aim of the present study was to evaluate the accuracy of cardiovascular risk monitoring in an outpatient sample of patients taking second-generation antipsychotics...
December 2, 2017: International Journal of Mental Health Nursing
https://www.readbyqxmd.com/read/29189863/-the-association-of-schizophrenia-with-chronic-non-transmissible-diseases
#9
Gricel Orellana, Matías Rodríguez, Nicolás González, Eduardo Durán
The life expectancy of patients with schizophrenia (SCH) is 11 to 20 years less than the general population. There is an association between SCH and various diseases and chronic conditions, highlighting the cardio-metabolic diseases. This association has been attributed to the use of antipsychotics, however, evidence has also shown intrinsic susceptibility of schizophrenic patients the development of chronic conditions. This review aims to update knowledge about chronic conditions such as cardiometabolic risk and sleep, bone and kidney disorders related to SCH...
August 2017: Revista Médica de Chile
https://www.readbyqxmd.com/read/29179831/improving-metabolic-monitoring-rate-for-young-people-aged-35-and-younger-taking-antipsychotic-medications-to-treat-a-psychosis-a-literature-review
#10
REVIEW
Gin-Liang Chee, Dianne Wynaden, Karen Heslop
Young people aged 35 and younger who are taking antipsychotic medications to treat a psychosis are a high risk for developing metabolic syndrome due to the adverse effects of the medications. This paper reports the finding of a review of literature to identify interventions to improve metabolic monitoring rates in this group. A review of 478 studies identified 15 articles which met the inclusion criteria. Five articles reported single-intervention studies and the remaining integrated two or more interventions to improve uptake level of metabolic monitoring...
December 2017: Archives of Psychiatric Nursing
https://www.readbyqxmd.com/read/29171377/-off-label-prescription-of-antipsychotics
#11
E Boot
Antipsychotic medication is frequently prescribed for off-label use in individuals with intellectual disability and elderly persons, in particular to reduce challenging behaviour. However, clear evidence for effectiveness is scarce and long-term use of antipsychotics is associated with a wide range of serious side-effects, including movement disorders and metabolic syndrome. Therefore, off-label use of antipsychotics in these populations has been widely debated. Nevertheless, non-pharmacological interventions alone are not always effective and a treatment attempt with an antipsychotic is sometimes inevitable...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29165095/metabolic-syndrome-and-cardiovascular-risk-in-people-treated-with-long-acting-injectable-antipsychotics
#12
Vanessa Sanchez-Martinez, Dolores Romero-Rubio, Maria Jose Abad-Perez, Maria Amparo Descalzo-Cabades, Sofia Alonso-Gutierrez, Jose Salazar-Fraile, Vicente Montagud, Lorenzo Facila
BACKGROUND: People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE: To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics...
November 20, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/29127566/monitoring-and-treating-metabolic-abnormalities-in-patients-with-early-psychosis-initiated-on-antipsychotic-medications
#13
Kevin M Bozymski, Jessica A Whitten, Mary E Blair, Ashley M Overley, Carol A Ott
Antipsychotic medications carry an established lifetime risk of metabolic syndrome. This retrospective chart review evaluated feasibility of a metabolic monitoring clinical decision support tool (CDST) for weight, lipid, blood glucose, and blood pressure management of 163 clients in an early psychosis outpatient clinic over 2 years. Each parameter had at least 98 (60.1%) clients with a recorded value, the most being documented for weight with 112 (68.7%) clients. CDST adherence ranged from at least 54.3-100% for non-pharmacologic interventions (e...
November 11, 2017: Community Mental Health Journal
https://www.readbyqxmd.com/read/29121623/metabolic-monitoring-in-new-zealand-district-health-board-mental-health-services
#14
Aimee Staveley, Ian Soosay, Anthony J O'Brien
AIM: To audit New Zealand district health boards' (DHBs) metabolic monitoring policies in relation to consumers prescribed second-generation antipsychotic medications using a best practice guideline. METHODS: Metabolic monitoring policies from DHBs and one private clinic were analysed in relation to a best practice standard developed from the current literature and published guidelines relevant to metabolic syndrome. RESULTS: Fourteen of New Zealand's 20 DHBs currently have metabolic monitoring policies for consumers prescribed antipsychotic medication...
November 10, 2017: New Zealand Medical Journal
https://www.readbyqxmd.com/read/29097257/a-randomized-13-week-study-assessing-the-efficacy-and-metabolic-effects-of-paliperidone-palmitate-injection-and-olanzapine-in-first-episode-schizophrenia-patients
#15
Manli Huang, Liang Yu, Fen Pan, Shaojia Lu, Shaohua Hu, Jianbo Hu, Jinkai Chen, Pingbo Jin, Hongli Qi, Yi Xu
BACKGROUND: This study was conducted to evaluate the efficacy and metabolic effects of paliperidone palmitate (PP) injections against oral olanzapine in first-episode schizophrenia (FES) patients. METHODS: Eligible patients were randomized to receive PP or olanzapine. Efficacy assessments and weight-related parameters were assessed at baseline, weeks 1, 5, 9, and endpoint or at early withdrawal. Lipid, glucose, insulin and prolactin were evaluated at baseline and endpoint or at early withdrawal...
October 31, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29057817/unresolved-issues-for-utilization-of-atypical-antipsychotics-in-schizophrenia-antipsychotic-polypharmacy-and-metabolic-syndrome
#16
REVIEW
Sang Won Jeon, Yong-Ku Kim
Atypical antipsychotics (AAP) are the prevailing form of schizophrenia treatment today due to their low side effects and superior efficacy. Nevertheless, some issues still need to be addressed. First, there are still a large number of patients with treatment-resistant schizophrenia (TRS), which has led to a growing trend to resort to AAP polypharmacy with few side effects. Most clinical treatment guidelines recommend clozapine monotherapy in TRS, but around one third of schizophrenic patients fail to respond to clozapine...
October 18, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29034440/risperidone-induced-metabolic-dysfunction-is-attenuated-by-curcuma-longa-extract-administration-in-mice
#17
Florent Auger, Françoise Martin, Olivier Pétrault, Jennifer Samaillie, Thierry Hennebelle, Mohamed-Sami Trabelsi, François Bailleul, Bart Staels, Régis Bordet, Patrick Duriez
Antipsychotics, such as risperidone, increase food intake and induce alteration in glucose and lipid metabolism concomitantly with overweight and body fat increase, these biological abnormalities belong to the metabolic syndrome definition (high visceral adiposity, hypertriglyceridemia, hyperglycemia, low HDL-cholesterol and high blood pressure). Curcumin is a major component of traditional turmeric (Curcuma longa) which has been reported to improve lipid and glucose metabolism and to decrease weight in obese mice...
October 16, 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/28980344/association-between-antipsychotic-treatment-and-leptin-levels-across-multiple-psychiatric-populations-an-updated-meta-analysis
#18
Renee-Marie Ragguett, Margaret Hahn, Giovanni Messina, Sergio Chieffi, Marcellino Monda, Vincenzo De Luca
OBJECTIVE: Antipsychotics (APs) are associated with metabolic syndrome, with increases in leptin proposed as an underlying mechanism of AP-induced weight gain. Currently available meta-analyses on this topic have limited their populations of interest to those diagnosed with schizophrenia. The purpose of this meta-analysis is to explore the relationship between leptin levels and AP use across multiple psychiatric diagnoses, and also in healthy controls. METHOD: Systematic electronic searches were conducted using PubMed and OVID: Medline...
October 5, 2017: Human Psychopharmacology
https://www.readbyqxmd.com/read/28969353/the-link-between-the-immune-system-environment-and-psychosis
#19
Rajiv Radhakrishnan, Muzaffer Kaser, Sinan Guloksuz
The last decade has witnessed a burgeoning interest in studies exploring the link between psychosis spectrum disorders (PSD) and altered immune function. While epidemiological and clinical studies point to evidence for increased peripheral inflammatory markers in PSD, it is not clear whether peripheral inflammation correlates with central inflammation in the brain. Furthermore, these studies are confounded by multiple methodological and disorder-related factors such as antipsychotic medications, smoking, obesity, and metabolic syndrome, all of which independently contribute to altered inflammation...
July 1, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28931411/topiramate-s-effectiveness-on-weight-reduction-in-overweight-obese-persons-with-schizophrenia-study-protocol-for-a-randomized-controlled-trial
#20
Miyuru Chandradasa, Layani Champika, Silumini de Silva, K A L A Kuruppuarachchi
BACKGROUND: Schizophrenia is a psychiatric disorder with a higher mortality than that of the general population. Most of the deaths are due to cardiovascular causes and are related to metabolic risks. This risk is due not only to antipsychotics but also to inherent factors of the disorder. Studies in the West have shown topiramate to be effective in schizophrenia to reduce weight gain and for symptomatic control. Whether this is effective for South Asians is not known. It is important because South Asians have a higher risk of metabolic syndrome...
September 20, 2017: Trials
keyword
keyword
73394
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"